These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
141 related articles for article (PubMed ID: 37348571)
1. Synthesis and characterization of a novel Sui Y; Duan X; Zhang J; Chu Y; Yang X Bioorg Med Chem Lett; 2023 Jul; 91():129382. PubMed ID: 37348571 [TBL] [Abstract][Full Text] [Related]
2. Duan X; Cao Z; Zhu H; Liu C; Zhang X; Zhang J; Ren Y; Liu F; Cai X; Guo X; Xi Z; Pomper MG; Yang Z; Fan Y; Yang X Eur J Nucl Med Mol Imaging; 2022 Feb; 49(3):1030-1040. PubMed ID: 34453203 [TBL] [Abstract][Full Text] [Related]
3. Synthesis and evaluation of a novel urea-based Zha Z; Ploessl K; Choi SR; Wu Z; Zhu L; Kung HF Nucl Med Biol; 2018 Apr; 59():36-47. PubMed ID: 29459281 [TBL] [Abstract][Full Text] [Related]
4. Optimization of ODAP-Urea-based dual-modality PSMA targeting probes for sequential PET-CT and optical imaging. Li Y; Duan X; Xu H; Zhang J; Zhou H; Zhang X; Zhang J; Yang Z; Hu Z; Zhang N; Tian J; Yang X Bioorg Med Chem; 2022 Jul; 66():116810. PubMed ID: 35580538 [TBL] [Abstract][Full Text] [Related]
5. What a difference a methylene makes: replacing Glu with Asp or Aad in the Lys-urea-Glu pharmacophore of PSMA-targeting radioligands to reduce kidney and salivary gland uptake. Kuo HT; Lin KS; Zhang Z; Zhang C; Merkens H; Tan R; Roxin A; Uribe CF; Bénard F Theranostics; 2022; 12(14):6179-6188. PubMed ID: 36168623 [TBL] [Abstract][Full Text] [Related]
6. Improve the Biodistribution with Bulky and Lipophilic Modification Strategies on Lys-Urea-Glu-Based PSMA-Targeting Radiotracers. Cai P; Tang S; Xia L; Wang Y; Liu Y; Feng Y; Liu N; Chen Y; Zhou Z Mol Pharm; 2023 Feb; 20(2):1435-1446. PubMed ID: 36696174 [TBL] [Abstract][Full Text] [Related]
7. Halogen Replacement on the Lysine Side Chain of Lys-Urea-Glu-Based PSMA Inhibitors Leads to Significant Changes in Targeting Properties. Xia L; Liu Y; Cai P; Feng Y; Yuan H; Tang S; Wang YW; Liu N; Chen Y; Zhou Z Mol Imaging Biol; 2023 Aug; 25(4):765-775. PubMed ID: 36695967 [TBL] [Abstract][Full Text] [Related]
8. Development of a Ga-68 labeled PET tracer with short linker for prostate-specific membrane antigen (PSMA) targeting. Moon SH; Hong MK; Kim YJ; Lee YS; Lee DS; Chung JK; Jeong JM Bioorg Med Chem; 2018 May; 26(9):2501-2507. PubMed ID: 29655611 [TBL] [Abstract][Full Text] [Related]
9. Synthesis and pre-clinical evaluation of a new class of high-affinity Kelly J; Amor-Coarasa A; Nikolopoulou A; Kim D; Williams C; Ponnala S; Babich JW Eur J Nucl Med Mol Imaging; 2017 Apr; 44(4):647-661. PubMed ID: 27847991 [TBL] [Abstract][Full Text] [Related]
10. Synthesis and biological evaluation of copper-64 radiolabeled [DUPA-6-Ahx-(NODAGA)-5-Ava-BBN(7-14)NH2], a novel bivalent targeting vector having affinity for two distinct biomarkers (GRPr/PSMA) of prostate cancer. Bandari RP; Jiang Z; Reynolds TS; Bernskoetter NE; Szczodroski AF; Bassuner KJ; Kirkpatrick DL; Rold TL; Sieckman GL; Hoffman TJ; Connors JP; Smith CJ Nucl Med Biol; 2014 Apr; 41(4):355-63. PubMed ID: 24508213 [TBL] [Abstract][Full Text] [Related]
11. Assessment of PSMA targeting ligands bearing novel chelates with application to theranostics: Stability and complexation kinetics of Kelly JM; Amor-Coarasa A; Nikolopoulou A; Kim D; Williams C; Vallabhajosula S; Babich JW Nucl Med Biol; 2017 Dec; 55():38-46. PubMed ID: 29055836 [TBL] [Abstract][Full Text] [Related]
12. Effects of Linker Modification on Tumor-to-Kidney Contrast of Kuo HT; Pan J; Zhang Z; Lau J; Merkens H; Zhang C; Colpo N; Lin KS; Bénard F Mol Pharm; 2018 Aug; 15(8):3502-3511. PubMed ID: 29920108 [No Abstract] [Full Text] [Related]
13. 68Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging. Eder M; Schäfer M; Bauder-Wüst U; Hull WE; Wängler C; Mier W; Haberkorn U; Eisenhut M Bioconjug Chem; 2012 Apr; 23(4):688-97. PubMed ID: 22369515 [TBL] [Abstract][Full Text] [Related]
14. Synthesis and Biologic Evaluation of Novel 18F-Labeled Probes Targeting Prostate-Specific Membrane Antigen for PET of Prostate Cancer. Harada N; Kimura H; Onoe S; Watanabe H; Matsuoka D; Arimitsu K; Ono M; Saji H J Nucl Med; 2016 Dec; 57(12):1978-1984. PubMed ID: 27417647 [TBL] [Abstract][Full Text] [Related]
16. Development of Potemkin R; Strauch B; Kuwert T; Prante O; Maschauer S Mol Pharm; 2020 Mar; 17(3):933-943. PubMed ID: 32011889 [TBL] [Abstract][Full Text] [Related]
17. Development and first-in-human study of PSMA-targeted PET tracers with improved pharmacokinetic properties. Hou H; Pan Y; Wang Y; Ma Y; Niu X; Sun S; Hou G; Tao W; Gao F Eur J Nucl Med Mol Imaging; 2024 Jul; 51(9):2819-2832. PubMed ID: 38683349 [TBL] [Abstract][Full Text] [Related]
18. (R)-NODAGA-PSMA: A Versatile Precursor for Radiometal Labeling and Nuclear Imaging of PSMA-Positive Tumors. Gourni E; Canovas C; Goncalves V; Denat F; Meyer PT; Maecke HR PLoS One; 2015; 10(12):e0145755. PubMed ID: 26700033 [TBL] [Abstract][Full Text] [Related]
19. Synthesis and preclinical evaluation of an Al Boschi S; Lee JT; Beykan S; Slavik R; Wei L; Spick C; Eberlein U; Buck AK; Lodi F; Cicoria G; Czernin J; Lassmann M; Fanti S; Herrmann K Eur J Nucl Med Mol Imaging; 2016 Nov; 43(12):2122-2130. PubMed ID: 27329046 [TBL] [Abstract][Full Text] [Related]